EU Orphan Drug Designation – overcoming regulatory challenges
Since the introduction of the EU orphan legislation in 2000, treatments for rare diseases now account for approximately 25% of all marketing authorization applications in the EU (EMA annual report, 2020). Clearly, the incentives offered by the ODD process have encouraged sponsors to pursue innovations in this domain. Yet while orphan status has been granted to more than 2,300 medicines, only 192 have received marketing authorization. There is no question that success or failure depends on multiple factors. But sponsors can amplify their prospects for gaining authorization by better understanding the regulatory considerations involved in bringing their innovations to patients awaiting them.
Related Insights
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Related Insights
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence
Aug 10, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022